| Investigation casts doubt on trial outcomes that underpin drug, and on safety procedures Related items from OnMedica Extending anticoagulation duration cuts risk of VTE recurrence NICE gives final approval to DVT drug Doctors and patients are ‘risk illiterate’ US doctor says FDA should have withdrawn rosuvastatin Drugs regulators “put profits before patients” |
Thursday, 4 February 2016
BMJ questions trial evidence for rivaroxaban
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment